Clinical Trial: Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187908) titled 'Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN' on April 22.

Brief Summary: Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN

Study Start Date: Jan. 01

Study Type: INTERVENTIONAL

Condition: Primary/Secondary Prevention High Risk for Febrile Neutropenia of Chemotherapy Regimens Intermediate Risk of Che...